Compare CENT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | ZYME |
|---|---|---|
| Founded | 1955 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 2022 |
| Metric | CENT | ZYME |
|---|---|---|
| Price | $39.33 | $24.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $50.00 | $32.75 |
| AVG Volume (30 Days) | 69.9K | ★ 494.4K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,304,000.00 |
| Revenue This Year | $1.60 | $63.10 |
| Revenue Next Year | $2.04 | $93.26 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | ★ 0.38 |
| 52 Week Low | $28.77 | $9.03 |
| 52 Week High | $41.25 | $28.49 |
| Indicator | CENT | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 65.96 | 56.44 |
| Support Level | $31.65 | $22.22 |
| Resistance Level | $40.81 | $27.52 |
| Average True Range (ATR) | 1.44 | 0.87 |
| MACD | 0.12 | 0.18 |
| Stochastic Oscillator | 84.73 | 78.33 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.